Novavax Exec Says U.S. Market Demand For Covid Vaccine This Fall Will Range From 80M-100M Doses; Has Contracts And Negotiated Pricing In Place For Covid Shots With U.S. CDC And Other Entities
Portfolio Pulse from Happy Mohamed
Novavax executive has stated that the demand for Covid vaccine in the U.S. market this fall will range from 80M-100M doses. The company has contracts and negotiated pricing in place for Covid shots with the U.S. CDC and other entities.
August 08, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax's Covid vaccine demand is expected to be high in the U.S. this fall, with contracts and pricing already negotiated with the U.S. CDC and other entities.
The high expected demand for Novavax's Covid vaccine in the U.S. this fall, along with the already negotiated contracts and pricing with the U.S. CDC and other entities, indicates a positive short-term impact on the company's stock. The news is highly relevant and important for Novavax as it directly relates to the company's main product and its sales.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100